Summary of minutes of EUCAST Steering Committee Meeting
Madrid, Spain, 26-27 September 2010

**Attending**

Dr Petra Apfalter PA EUCAST Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Clinical Data Co-ordinator Spain
Prof Luc Dubreuil LD CA-SFM France
Dr Christian Giske CG SRGA Sweden
Dr Robin Howe RH BSAC United Kingdom
Dr Marina Ivanova MI EUCAST Estonia
Prof Gunnar Kahlmeter GK Chairperson Sweden
Dr Johan W. Mouton JM CRG The Netherlands
Prof Arne Rodloff AR DIN Germany
Dr Martin Steinbakk MS NWGA Norway

**Apologies**

Prof Claude-James Soussy CS CA-SFM France
Prof Alasdair P. MacGowan AM BSAC United Kingdom

1 **Chairman’s welcome**

GK expressed the sadness of the Steering Committee at the loss of Helmut Mittermeyer, who died on the journey home from the last meeting. His active support for EUCAST was acknowledged and he will be sorely missed. Helmut's close colleague, Petra Apfalter, was welcomed as a new member representing the EUCAST General Committee. RH represented BSAC in place of AM.

2 **Minutes of meeting of 5-6 July 2010** The minutes were accepted as a correct record.

3 **Matters arising from minutes of 5-6 July 2010**

A paper for CMI explaining ECOFFs is to be prepared.

MIC data on anaerobes is to be added to the MIC database.

The revised expert rules computer program is to be assessed.

Noted that unrestricted research donations can be made to ESCMID by companies.

Oxacillin MIC distributions for \textit{S. saprophyticus} will be prepared as part of work on disk diffusion breakpoints for coagulase-negative staphylococci.

ECDC will be asked to provide a list of all agents included in resistance surveillance programmes.

A table is being prepared detailing the status of European countries with regard to EUCAST breakpoints and methods.

EUCAST statutes have been revised and will be sent to the General Committee for comment.

Breakpoints for mupirocin and the rationale document have been published on the EUCAST website. Disk diffusion test criteria are being developed.

EUCAST SOPs on breakpoint setting will be published on the EUCAST website.

EUCAST comments on the EMA draft guidelines for industry have been sent to EMA.

A document on manufacturers’ readiness for EUCAST methods and breakpoints is being updated.

A letter clarifying the relationship of EUCAST to manufacturers has been sent to Rosco.

A note explaining that the intermediate category is not specified but lies between the S and R breakpoints has been added to each breakpoint spreadsheet.
4 New drugs See item 12.

5 Status of EUCAST rationale documents The current status of documents was reviewed and several drafts were updated.

6 ECDC No new information.

7 Expert rules subcommittee The draft of version 2 was reviewed and is now almost complete.

8 Antifungal susceptibility testing subcommittee It is expected that several proposed breakpoints and rationale documents will be sent for consultation in the near future.

9 Anaerobe subcommittee The anaerobe methods study is still in progress.

10 Organisms without EUCAST breakpoints Discussions with H. pylori and C. difficile study groups are continuing. Developments on Campylobacter spp., Legionella spp., Listeria spp., Actinomycetes spp. and P. multocida were reviewed. B. cepacia was discussed in detail and the problems of poor reproducibility of in vitro tests and lack of clinical correlation noted. It was agreed that no specific work would be done on rapidly growing mycobacteria or Bordetella spp. Work is underway or data being collected on Corynebacterium spp., S. maltophilia, Nocardia spp. and Streptomyces spp.

11 Cefazolin breakpoints for Enterobacteriaceae Most countries do not need breakpoints.

12 New cephalosporin The agent was presented to EUCAST by the corresponding pharmaceutical company.

13 ESCMID/ECCMID For the ECCMID Milan meeting in 2011 a half-page flyer will be produced for the programme booklet outlining the various activities of EUCAST.

14 EMA No new information.

15 CLSI No new information.

16 Antiviral resistance surveillance A document reviewing current activity will be sent to ECDC.

17 Implementation of EUCAST breakpoints A document on NAC guidelines will be posted on the EUCAST website. It was noted that it was useful to produce an annual list of changes to EUCAST guidelines tailored for each country.

It was noted that NACs have been set up and adoption of EUCAST breakpoints agreed in several countries. Adoption of EUCAST breakpoints and methods is being discussed in several countries.

The EUCAST disk diffusion method is currently being used in at least 30 laboratories. Multiple disk diffusion development projects are underway or planned for the next few months.

18 Agents without breakpoints Development of breakpoints for sulphonamides, nalidixic acid (screening), high level streptomycin resistance in enterococci, spiramycin, cefradine, cephalothin, cefaperazone, cefoxitin (screening) and several topical agents was discussed.

19 Website There have been multiple changes to the website and these will be ongoing as the site develops. A poster on navigation around the EUCAST website will be produced.

20 Any other business Cefixime breakpoints for N. gonorrhoeae, breakpoints splitting wild types and direct susceptibility tests will be reviewed at the next meeting.


Ratified summary of minutes of meeting 26-27 September 2010. Prepared by DB, GK and RC